Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06929286 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
A Phase 3 study of Non-muscle Invasive Bladder Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT06929286 is a Phase 3 study of Non-muscle Invasive Bladder Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 125 participants, below the 229-participant average among 28 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06929286, a Phase 3 study of Non-muscle Invasive Bladder Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the effectiveness of different FDA-approved/NCCN-recommended drug treatments for NMIBC. In particular, the FDA-approved drug nadofaragene firadenovec will be compared to usual care with other NCCN-recommended standard treatments for NMIBC (gemcitabine with or without docetaxel, mitomycin, re-treatment with BCG, or pembrolizumab).
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Gemcitabine
- DRUG Nadofaragene Firadenovec
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-04-11 |
| Est. Completion | 2028-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06929286
The ClinicalTrials.gov registry entry for NCT06929286 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 229-participant average among 28 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (45% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT06929286 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06929286 about?
NCT06929286 is a clinical study titled "A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)". The purpose of this study is to compare the effectiveness of different FDA-approved/NCCN-recommended drug treatments for NMIBC. In particular, the FDA-approved drug nadofaragene firadenovec will be compared to usual care with other NCCN-recommended standard treatments for NMIBC (gemcitabine with or ...
What is the current status of trial NCT06929286?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2025-04-11. Estimated completion is 2028-04.
What conditions does trial NCT06929286 study?
This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer.
What interventions are being tested in trial NCT06929286?
The interventions under investigation include: Docetaxel (DRUG), Gemcitabine (DRUG), Nadofaragene Firadenovec (DRUG).
Who is sponsoring clinical trial NCT06929286?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06929286 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-muscle Invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Intravesical BCG vs GEMDOCE in NMIBC
ACTIVE NOT RECRUITING · Phase 3
-
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
ACTIVE NOT RECRUITING · Phase 3
-
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
ACTIVE NOT RECRUITING · Phase 3
-
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.